AN2 Therapeutics Reports Q2 2024 Results And Recent Highlights
13 Aug 2024 //
BUSINESSWIRE
AN2 Therapeutics shares fall after pausing lung disease study enrollment
13 Feb 2024 //
REUTERS
AN2 Therapeutics commences Phase 2/3 Clinical Trial Evaluating Epetraborole
13 Sep 2023 //
BUSINESSWIRE
AN2 Therapeutics Initiates Pivotal PII/III Trial Evaluating Epetraborole
29 Jun 2022 //
GLOBENEWSWIRE